Mandate

Vinge advises on the sale of Fiomi Diagnostics AB

March 05, 2012

Vinge has advised the shareholders of Fiomi Diagnostics AB in connection with the sale of the shares in the company to Trinity Biotech plc, which is quoted on NASDAQ. Fiomi, which is based in Uppsala, develops platforms for point-of-care diagnostics based on a technology which originated from Uppsala Åmice AB.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, associates Claes Henriksson and Louise Markgren as well as project assistants Ida Norlin

Related

Vinge advises Adelis Equity Partners on the establishment of a continuation fund

Vinge has advised Adelis Equity Partners on the establishment of a continuation fund to Adelis Equity Partners Fund II. The continuation fund is a so-called dual-asset vehicle which will invest in Presto and HVD Group (Hantverksdata) – both current portfolio companies of Adelis Equity Partners Fund II. The continuation fund, in which HarbourVest Partners will be the largest investor, will have EUR 430m in commitments and will invest alongside Adelis Equity Partners Fund III and the Adelis team.
February 21, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Wavecon

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Wavecon AB (”Wavecon”).
February 14, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Projektstaben

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Projektstaben i Sverige AB (”Projektstaben”).
February 14, 2024